I’ve been pressing the federal government on its oversight of the fire ant eradication program. While Canberra funds half of this national program, responsibility for delivery lies with the Queensland government. Landowners are reporting serious issues — intimidation, property damage, and environmental harm — yet the department insists there’s “no evidence” of wrongdoing.

I asked questions about residents’ rights to refuse access when health or safety is at risk. What happens if someone has asthma and chemical exposure could trigger an attack? What about pets, livestock, or crops at risk? The department wouldn’t give me an answer. Even more alarming, I’ve received reports of chemicals being used unlawfully — S-methoprene dumped into waterways, aerial spraying of pyriproxyfen in areas with no fire ants — all in breach of permit conditions.

And then there’s Dawson Creek in Samford Valley where locals report native species have been killed. Where’s the environmental safety research proving these chemicals are safe for people and wildlife? The department claims the program is “supported by science,” and insists it won’t suspend funding—even when breaches occur. That’s taxpayer money being spent on a program that could be putting lives, health, and ecosystems at risk.

I’m not backing down. Biosecurity matters, yet it should never come at the expense of people’s rights, health, or trust.

If you’ve had problems with the fire ant program, please reach out — I’d like to hear from you.

— Senate Estimates | December 2025

Transcript

Senator ROBERTS: Thank you for appearing again today. What oversight is the federal government exercising to ensure the states are successful in eradicating fire ants and are doing so safely?

CHAIR: I will say that we have touched on fire ants, but please feel free.

Senator ROBERTS: Yes. I raised this at the last Senate estimates. I’ve got quite a few questions.

CHAIR: Carry on.

Ms Sawczuk: As we mentioned a moment ago, we continue chairing the national governance—the national management group—around the program. There is a program-level meeting and also a consultative meeting. That is happening regularly, and the next national governance meeting is on 15 December. Taking on board the concerns that you raised at the last estimates hearing and correspondence that has been provided to the department but also to the program in Queensland, we have been engaging with the program to pass on the specific feedback that has been provided. They have confirmed that they are taking on board any considerations raised by landowners, but there has been no damage to property and also no unlawful behaviour in regard to accessing properties for treatment et cetera. The safety of the program is absolutely critical. It’s something that is discussed at the national management meetings in particular, and we take quite seriously any concerns that have been raised around specific treatment types, whether it’s broadscale treatment or direct nest injection. The APVMA is the authoriser of those particular treatments and can confirm that the program has been undertaking independent toxicology analysis, which has found that there is no direct correlation with any negative impacts to animals et cetera around the fire ant treatment.

Senator ROBERTS: Well, I’m stunned. When you say ‘take on board’, what do you mean? What action do you take specifically to hold them accountable?

Ms Sawczuk: We directly engage at all levels.

Senator ROBERTS: What do you mean by that?

Ms Sawczuk: We meet with the program to talk about the specifics.

Senator ROBERTS: Where do you meet?

Ms Sawczuk: Virtually and face to face, and quite regularly. Every piece of correspondence that has been sent through is provided directly to the program, and then we have followed in meetings to understand the specific circumstances. While there are some claims, there is definitely no evidence that would warrant concerns about anything untoward about the behaviour of the program. I appreciate that there are some sensitivities for specific landowners et cetera, but all of the treatment, and all of the action by the program, has been within the Queensland biosecurity legislation.

Senator ROBERTS: There have been assaults on people, injuries to innocent people. There has been complete disregard for people’s health. There have been violations of the permits, which I’ll get onto. So I don’t
accept your response at all. Last time we appeared at Senate estimates on this topic, we were deluged with people saying they would contact you. Have you been contacted by residents?

Ms Saunders: We have received correspondence since our last hearing, and, as Ms Sawszuk just outlined, all that information is provided to the program, who’s ultimately accountable for delivery, compliance, assurance and oversight of the work that occurs.

Senator ROBERTS: Who is responsible?

Ms Saunders: The relevant state department in Queensland is responsible. There are ongoing discussions with them in regard to the issues that have been raised, but, ultimately, it’s the Queensland government that is
accountable for delivering the program.

Senator ROBERTS: So the state is responsible but you’re funding it to do these activities.

Ms Saunders: The nation, because it’s a national program, to which we contribute funding—correct.

Senator ROBERTS: The majority of funding.

Ms Saunders: It’s 50 per cent.

Senator ROBERTS: For eradication. You don’t seem to be aware of the overreach and intimidating tactics being undertaken by the state government, particularly in South-East Queensland, forcing their way onto
properties unlawfully, causing fear and distress to landowners, upsetting women and terrifying crying children, polluting the environment, negligently and wilfully killing fauna and pets. Are you aware of those?

Ms Saunders: I know you’re disappointed with the response that we give you, as a department, but I can only give you the same advice I gave you at the last hearing on these matters, and that is that we are not accountable or responsible for the issues you’ve raised, nor do we have evidence of them.

Senator ROBERTS: Since when is it okay for gates and fences, with your funding, to be broken down, with police threatening those with reasonable excuses who withhold consent—for strangers to force their way onto
properties and sneakily and deceptively distract people from their properties, with a view to spreading poison, when there are no fire ants on their property, not even in the valley?

Ms Saunders: I’m not sure what else I can add to our earlier evidence on this.

Senator ROBERTS: This is exactly what happened recently at Beechmont and Laidley, when property was damaged and officers behaved like criminals in a home invasion while trespassing on private land. The violence came from the officers, not the landowners. The landowners have been professional and peaceful. Why?

Ms Saunders: These are the responsibilities of the state government. I’d really encourage those allegations and concerns being directed to them. As indicated by the deputy, the legislation which they’re operating in
compliance with is entirely the responsibility of the state government.

Senator ROBERTS: But you’re funding it. I attended another property some kilometres away from the two locations I mentioned that had multiple fire ant nests—I saw them six metres apart in places and two or three
metres apart in places—that the program refused to attend and treat. Why is that?

Ms Saunders: I can’t comment.

Senator ROBERTS: Would you like the name of the property?

Ms Saunders: Certainly, we’re happy to take any information you have. We would relay it to state government for action, noting we have no authority.

Senator ROBERTS: A property owner may obstruct and refuse access to officers if they have a reasonable excuse. Is it a reasonable excuse to obstruct when a resident has an illness, such as asthma or other respiratory
ailment, confirmed by a medical certificate as likely to be made worse by exposure to toxic chemicals, particularly when being sprayed? Is that a reasonable excuse?

Ms Saunders: I’m not prepared to comment.

Senator ROBERTS: Is it a reasonable excuse to obstruct when the chemicals represent a threat to domestic animals—dogs, cats and birds—if they’re exposed to the toxic chemicals, including chickens?

Ms Saunders: I’m not prepared to comment.

Senator ROBERTS: Is it a reasonable excuse to obstruct when the chemicals that you’re funding represent a threat to poultry, livestock and fruit and vegetables growing on the property?

Ms Saunders: If you have a long list of allegations, we’re happy to take those allegations and raise the matters with the Queensland government.

Senator ROBERTS: Okay. I will do that with most of these questions. Is it a reasonable excuse to obstruct when the chemicals are not being administered according to the safety requirements under the permits issued by
the APVMA?

Ms Saunders: I don’t have a comment.

Senator ROBERTS: Just yesterday I was told—this is so common—that the program distributed S methoprene directly into a Samford waterway, against the safety rules for application, by way of a drone. Are you aware of that?

Ms Saunders: No.

Senator ROBERTS: Aerial application of pyriproxyfen is occurring on a wide scale on areas where no fire ants have ever been identified, when the permit number PER87728 clearly states by way of restraint:
DO NOT apply as a preventative measure for Red Imported Fire Ant control. If the permit has changed, why? Are you aware of that?

Ms Saunders: No.

Senator ROBERTS: Is it a reasonable excuse to obstruct when the administering authority has already admitted to disastrously polluting a significant waterway in the Samford Valley near Brisbane, Dawson Creek,
killing extensive native water, reptile and insect species? I’ve seen that. Is that a reasonable excuse?

Ms Saunders: I couldn’t comment on that.

Senator ROBERTS: Okay.

Senator WHISH-WILSON: Did you take photos?

Senator ROBERTS: Yes.

Senator WHISH-WILSON: Can you produce them for us?

Senator ROBERTS: The locals can.

Senator WHISH-WILSON: What about you? You said you took photos.

Senator ROBERTS: No, the party I was with took photos.

Senator WHISH-WILSON: Oh, I see.

Senator ROBERTS: Where is the environmental safety research that’s been done to establish the safety of humans and our native birds and small animals when poisoned insects form part of their food chain? Have you
done that?

Ms Saunders: I’ll hand over to Dr Bertie Hennecke—he can probably comment further—but the program is absolutely supported by scientific evidence and safety. It’s been looked at nationally, with people who have
credible experience in this field, all of whom are satisfied with the arrangements that are in place and the chemicals that are being used for the purpose intended.

Senator ROBERTS: In distributing these chemicals, they’re breaching the permits—they’re breaching the authorisation—to use the chemicals. Does that bother you? You’re funding it.

Ms Saunders: If there’s evidence of that, we’re happy to take that evidence and take up the matter with the Queensland government.

Senator ROBERTS: Will DAFF step up to pay compensation to those affected by the misapplication of the Fire Ant Eradication Program?

Ms Saunders: It wouldn’t be the responsibility of the department—

Senator ROBERTS: You’re funding it.

Ms Saunders: to do that.

Senator ROBERTS: Why are you funding this using taxpayer money, doing injury to the environment and to people?

Ms Saunders: It’s a national program aimed at eradicating red imported fire ants. It’s that simple. We know it’s incredibly invasive and, if it were to take hold, would have catastrophic implications for the country. That’s
why we’re doing it.

Senator ROBERTS: So why are you putting lives and the health of humans and the environment at risk?

Ms Saunders: We don’t have evidence of that.

Senator ROBERTS: Would you like some?

Ms Saunders: As I’ve said several times now, I’m happy to take information you have, and we’ll take it up with the Queensland government.

Senator ROBERTS: Will you stop funding this program, or at least suspend funding of this program?

Ms Saunders: No, we won’t.

Senator ROBERTS: Okay.

In early December 2025, the U.S. FDA announced immediate and sweeping reforms to its vaccine approval and monitoring processes. These changes include stricter clinical trials, restrictions on high-risk groups such as pregnant women, and a comprehensive overhaul of vaccine safety monitoring.

I asked the Australian TGA whether they were following these developments and if there was a need for Australia to adopt similar measures. Their response was a “no,” wrapped in many pointless words.

Health Secretary Kennedy is making great progress in dragging the medical establishment back to the center. At present, I believe pharmaceutical companies and their profits exert too much influence on our health administration, to the detriment of common sense, honesty, and duty of care.

I will continue to hold the TGA to account.

– Senate Estimates | December 2025

Transcript

Senator ROBERTS: For now. The FDA announced immediate and sweeping reforms to their vaccine approval and monitoring processes, including stricter clinical trials; restrictions on high-risk groups, such as
pregnant women; and an overhaul of the vaccine safety monitoring system. This is going on under a new administration. The reforms closely mirror measures which operated in Australia until COVID, when our safety
assessments and monitoring were watered down with fast-track approval and emergency-use authorisation for a multitude of drugs. Will you accept that weak approval processes, high-adverse events and blanket denials that anything is wrong have undermined confidence in the entire health system in this country?

Prof. Lawler: There are a couple of things there, if I might comment. We didn’t use emergency-use authorisation. We adopted what is called a provisional pathway—

Senator ROBERTS: It’s equivalent.

Prof. Lawler: It’s not equivalent; it’s quite different. The reason that we undertook it was that, like the rest of the world, we recognised that there were risks that the community was facing, and we worked very closely with other regulators to understand what was emerging. Tonight, you previously mentioned relying on the FDA. It’s really important that, when we talk about reliance, it’s a specific term. It’s not like, if the FDA has approved it, then we automatically register it—

Senator ROBERTS: I’m just using Professor Skerritt’s words.

Prof. Lawler: I wasn’t here when Professor Skerritt gave you those words; I’m just trying to explain where we’re at.

Senator ROBERTS: He said he didn’t do any testing here—

CHAIR: Senator Roberts, can we let Professor Lawler finish his answer, please.

Prof. Lawler: It’s not like, if the FDA hasn’t approved it, we say, ‘You shall not pass.’ What happens is that we look to the information that other regulators have when making our own decisions. I think the important thing as well to note is that we do very much rely on our approvals. We do have, as other regulators have, both pre-market and post-market evaluation and monitoring. But the point that you made about trust is a very important one. We had a presentation at our International Coalition of Medicines Regulatory Authorities earlier this year about trust. There was a very strong driver of trust in institutions, in regulations and in health professionals. The very strong downward driver of it is misinformation and disinformation. Part of the challenge that we have is that, as we hear very frequently, there are a lot of studies, for instance, of very low quality that are being taken up and used as evidence or proof of causal links that just do not exist. Part of the challenge we have is that we do strive to rebuild trust. On two occasions in the last two months, the chief medical officer and I have endeavoured to do that through public statements, and it is a constant battle.

Senator ROBERTS: It’s something we’ve found agreement on. I understand there was a paper in the Lancet a few years ago that said that 50 per cent of medical papers are not valid. Now, we’ve got increasing knowledge coming out and evidence showing that big pharma has heavily influenced the scientific papers and has corruptly done so. This is my last question. Will you monitor the changes in the United States in case the new team under Kennedy is actually right about what has gone before them and right about the changes being necessary?

Prof. Lawler: We monitor all of the developments by our international collaborative partners in regulation.

CHAIR: Thank you.

The U.S. CDC has changed its guidance on vaccines. The new guidance states that it is not possible to declare vaccines safe because there is no proof that they are. I asked the TGA whether they had changed their own position as a result. The ensuing discussion was pure semantics, as the TGA tried to avoid agreeing with the CDC.

For the record, the theory of logic states: “An outcome that has not been proven impossible may be possible.” To avoid what comes next—a simple question—the TGA had to deny basic logic. That question was: If it MAY be possible, shouldn’t you take a fresh look?

In previous Estimates hearings, I have presented the TGA with peer-reviewed, published papers showing that adjuvants (preservatives) in vaccines can cause autism. These papers actually show causation—the damage to the brain caused by adjuvants used in vaccines.

The testimony from Professor Lawler was simply wrong, and I will revisit this question in the February Estimates.

— Senate Estimates | December 2025

Transcript

Senator ROBERTS: Now, I’d like to turn to vaccines and autism again. In America, the CDC have changed their guidance on vaccines and autism. The guidelines now read:

… there are still no studies that support the claim that any of the 20 doses of the seven infant vaccines recommended for … the first year of life do not cause autism.

The American FDA has accepted that vaccines may cause autism because there is no study to show they are safe. Yet I’ve sat here repeatedly, including earlier tonight, and been told by the TGA over and over again that they are safe. You can’t be right. Either there is proof they are safe, or there is not. Which is it?

Prof. Lawler: I discussed this at length with Senator Antic. The policy decisions and announcements of the FDA are matters for the FDA, and those questions should be directed to them. I would just highlight a couple of your question.

Senator ROBERTS: Correct.

Prof. Lawler: That’s not what they said.

Senator ROBERTS: That’s correct.

Prof. Lawler: They’ve not said that vaccines cause autism.

Senator ROBERTS: They’ve said:

… there are still no studies that support the claim that any of the 20 doses of the seven infant vaccines recommended … do not cause autism.

Prof. Lawler: I think you went on to say at the end of your question—and please correct me if I’m wrong—that the FDA is thereby saying that vaccines cause autism.

Senator ROBERTS: No. I said the FDA, though, has accepted that vaccines may cause autism because there are no studies to show they are safe.

Prof. Lawler: Again, the three-point statement that appeared in November on the CDC’s website, which replaced its previous guidance on vaccines and autism, was of a particular wording. It seemed to me to quite
clearly say that, in its view, it cannot be said that vaccines do not cause autism, because no studies have shown that they do not cause autism. As I mentioned previously in my response to the question by Senator Antic, there is a fundamental scientific challenge in stating that something exists because you haven’t been able to prove that it doesn’t. The scientific process is that an individual or a party that makes a scientific claim holds the onus to provide the evidence that supports that claim. For instance, if you’re claiming that vaccines cause autism, the obligation is on you or another person who’s claiming that to demonstrate the evidence that supports that claim. The challenge that we have in that space is that a significant amount of the initial conversation around vaccines causing autism arose from a 1997 article by then doctor Andrew Wakefield that was published in the Lancet and subsequently retracted and thoroughly debunked because there were personal, professional, ethical and methodological conflicts and flaws. Since then, there have been multiple studies over decades involving millions of children and adults who have received different types of vaccines over different years, and, in that time, there has been no demonstrated causal or associative link between vaccines and autism. So, as I say, if there is a claim there, it has never been substantiated by rigorous and dependable evidence, and all of the evidence that we have is supportive of the view that there is no link between vaccines and autism.

Senator ROBERTS: In my view—and I think this is probably correct—the approver has the onus to say that something’s safe. The approver is you, the TGA. According to FOI No. 1345-01, you had 43 sudden, unexpected deaths reported on your Adverse Event Management System following injection of the Infanrix hexa vaccine. Are none of those caused by the vaccine?

Prof. Lawler: I’ll throw to Dr Dascombe, who’s online, to respond to that. I will just say, initially, as I have said in response to your questions and the questions of others and indeed in the conversation that we had
previously this evening around mesh, the role of the regulator is to ensure that the risks are managed appropriately such that there is an effective balance for the community between access to a therapeutic product and the benefit derived from the product, and the risk that’s presented. As we’ve discussed on a number of occasions, overwhelmingly, for the COVID vaccine and for other vaccines, the risk-benefit profile is positive. Dr Dascombe, I’ll ask you to respond as well.

Dr Dascombe: To go to both of your questions, Senator, Professor Lawler has comprehensively answered on two occasions now tonight questions around the updated guidance from the US CDC. There are a couple of things that I’d reaffirm there, particularly from a post-market regulation of vaccines perspective. The TGA, like our international counterparts, takes an evidence based approach to the regulation of vaccines registered in Australia. This means that our regulatory decisions are based on the weight of available scientific evidence. There are a couple of key points worth confirming. There is no scientific evidence of a causal link between autism and any vaccine or vaccine ingredient. There is a substantial body of scientific evidence to refute the claim that vaccines are linked to autism. Neither the TGA nor any international regulator has detected or confirmed a safety signal for autism in any vaccine. Those are key points to reiterate, to your first question. To your second question, around reported adverse events with the Infanrix hexa vaccine on our Adverse Event
Management System, as you know, this is a system that relies on spontaneous reports from healthcare professionals, consumers, states, public health units and medicine sponsors. The existence of a report in that system and a report made to us doesn’t necessarily confirm that the vaccine has caused that death. We encourage reporting of all adverse events, even if there’s only a small chance that the vaccine is related to that death.

Senator ROBERTS: Thank you.

Prof. Lawler: Thank you for that, Dr Dascombe. I would also just reflect on your comment earlier about the onus on the approver to ensure that something is safe. That is correct. The challenge that every regulator in the world faces is that the only way to ensure that there is no risk in a product is to not approve any product for supply in the country. That’s the only way, and then the public would be quite rightly clamouring for access to goods that are enjoyed by populations around the world. So the role of the regulator here in Australia, as in other countries, is to appropriately assure itself that the evidence indicates that the risk-benefit profile is positive. As Dr Dascombe’s indicated, there’s no identified causal link between vaccines and autism.

Senator ROBERTS: You weren’t here, but I asked Professor Skerritt a question about the testing of the COVID Pfizer shots in Australia. He said, ‘Oh, no, we didn’t do any testing; we relied upon the FDA in America.’
At that time, it had been already been stated that the FDA did no testing itself and relied on Pfizer, and Pfizer cut short its trials because of the number of people who died. So we had a failed study that led to the approval of vaccines—of COVID injections—in this country, and no-one knew about it, yet it was open public knowledge in the United States. Let me continue. A Korean study published in Biomarker Research in September this year followed up 8.4 million Koreans and found as follows: within a 12-month period following their COVID jab, the vaccinated group had a 27 per cent greater chance of being diagnosed with cancer when compared to an unvaccinated group. This was a massive study. This does not prove causation, although many studies I have shared with you prove how these products cause cancer. It does prove correlation. Do you still maintain that COVID vaccines are safe?

Prof. Lawler: I do not recall, Senator, an article that you shared with me that does prove causation between these vaccines and cancer. Also, given the need to analyse the documents, I don’t have the article that you’re
describing in front of me, so I think it would be inappropriate for me to comment on it specifically.

Senator ROBERTS: Okay. I’ll check that. On 28 November 2025, Dr Vinay Prasad, director of the American FDA’s Center for Biologics Evaluation and Research, sent an email first reported by the New York Times. It
described findings from a recent internal FDA review of paediatric deaths reported to the Vaccine Adverse Event Reporting System, VAERS, between 2021 and 2024. According to the memo, an analysis of 96 reported
paediatric deaths among people aged from seven to 18 concluded that at least 10 were causally linked to COVID 19 vaccines, primarily due to vaccine induced myocarditis. Prasad describe this as a ‘profound revelation’. Professor Kidd, do you acknowledge that paediatric vaccines can cause death?

Prof. Kidd: I’m going to have to take that on notice.

Senator ROBERTS: You can’t acknowledge it or you can?

Prof. Kidd: I’m going to take it on notice.

Senator ROBERTS: The FDA analysis—

Prof. Lawler: I’m happy to provide some comment on that if you like, Senator.

Senator ROBERTS: Sure.

Prof. Lawler: We did respond to questions about Dr Prasad’s announcement earlier this evening when questioned by Senator Antic. As far as I’m aware—Dr Dascombe, please feel free to correct me—we have not at
this stage been provided with information regarding that. As we have indicated previously, we rely not only on our own information that comes through our own adverse event monitoring system but also on signals that come from other regulators. This is not a signal that has been replicated, to my knowledge, in other regulators. As I say, we have not had detailed information regarding Dr Prasad’s claim shared with us.
In terms of the question that you posed to Professor Kidd, one of the reasons we have robust postmarket vigilance in place for medicines, devices and, in fact, all therapeutic goods that we regulate is that we recognise
that individuals sometimes react to medicines. To give you an example, we have a number of other medicines—non-vaccine medicines—to which individuals can have allergic reactions. So it would be inappropriate, I think, for either Professor Kidd or me to say that people can’t react to these things. Our role as the regulator is to ensure that appropriate systems are in place to identify safety signals as they arise, to analyse them, to understand them and to respond to them in an appropriate way.

In this session of Senate Estimates, I sought clarity on the operation of the Indigenous Procurement Policy (IPP). There’s a lot of confusion around whether government contracts over $7.5 million must be awarded to Indigenous businesses.

After questioning officials, it’s clear that this isn’t the case. The policy doesn’t mandate awarding contracts based on race—it requires that, for large contracts delivered in Australia, companies meet minimum Indigenous participation targets. These targets can be achieved through employment, subcontracting, or a combination of both.

Australians deserve transparency on how their taxpayer money is spent. While the government says these measures aim to close the gap, we must ensure that procurement decisions remain focused on value for money and fairness for all. I’ll continue to scrutinise policies that risk introducing race-based preferencing into government processes. Accountability matters.

— Senate Estimates | December 2025

Transcript

Senator ROBERTS: Alright, I’ll move on to clarifying the operation of the Indigenous procurement policy. I’m told that every Commonwealth agency is obligated to choose Indigenous content on contracts over $7.5
million, so if there’s a choice between a white employer and an Aboriginal employer the government must choose the Aboriginal agency. Is that correct?

Ms Guivarra: I think you’re referring to mandatory minimum requirements which actually relate to employment. There are mandatory set-aside requirements for contracts valued between $80,000 and $200,000,
where, all other things being equal, if it is an Aboriginal organisation, then a preference is allocated.

Senator ROBERTS: Are you talking about employment or expenditure?

Ms Guivarra: No. I think the figure you were referring to was the $7.5 million, which refers to the mandatory minimum requirements. For contracts over $7½ million, there’s an employment target.

Mr Dexter: That’s right. The $7.5 million threshold is one part of the IPP. It’s the mandatory minimum Indigenous participation requirement. It does not require Commonwealth agencies to grant those contracts to
Indigenous businesses. That’s not a feature of the IPP.

Senator ROBERTS: So if the contract is granted, then they must hire—

Mr Dexter: What it does require is for there to be mandatory minimum Indigenous participation targets as part of that contract, and that’s for contracts delivered wholly in Australia valued at $7.5 million or more in 19
industry categories. That’s been one of the three parts of the IPP since 2015.

Senator ROBERTS: Minister, what’s the basis for the government engaging in race based preferencing?

Senator McCarthy: I reject outright your assertion there. I have called on all senators and members of parliament to join me in trying to close the gap in terms of the targets we’re trying to achieve. Those targets are
specifically aimed at trying to improve Indigenous employment and Indigenous businesses, and we make no apologies for that.

Senator ROBERTS: So, all things being equal, an Aboriginal will be preferred based on race to a non Aboriginal?

Mr Dexter: No, that’s not correct.

Senator ROBERTS: I’m exploring this.

Mr Dexter: I’m trying to be helpful in clarifying that that’s not a requirement of the policy. In selecting those contracts, Commonwealth procurement officials are always required to demonstrate value for money for the
contract, whether there are MMRs applied for the contract or not.

Senator ROBERTS: But then there will be hiring criteria that are favourable to Aboriginals if the company gets a contract. Is that correct?

Mr Dexter: How the supplier meets those targets is entirely a matter for the company. They can do it through subcontracting arrangements, they can do it through employment arrangements or they can do it through a
combination of both.

Senator ROBERTS: Okay. Thank you very much.

I spoke with Ms. Liz Hefren-Webb and raised the issue of overcharging by service providers, which is depleting the limited funds available through Aged Care packages.

I highlighted the case of David and Sandra Smith, whose package was debited $3,000 for a small, incomplete gardening job. As a result, they were unable to access certain medical services because they could not afford them. Their complaints to the Commission fell on deaf ears; the Commission provided no explanation for its decision and refused to discuss the matter with the Smiths.

I also raised the case of Mr. Garry Bayliss, who had $14,000 taken from his My Aged Care account simply to replace some timber railings on a fence. Again, the Commission failed to take any action to remedy the situation.

Ms. Hefren-Webb suggested sending the details to the Agency for re-examination. I also raised concerns about the proposed introduction of co-payments into Aged Care packages, which will reduce the actual services provided. Many recipients cannot afford these additional costs, with some services charged at rates of $100 per hour or more. I stated that these shortcomings do not constitute quality care and amount to institutional elder abuse.

– Senate Estimates | December 2025

Transcript

Senator ROBERTS: Thank you for appearing today. Since the introduction of personalised aged-care packages, there has been an abject failure, it seems, of monitoring how funds allocated are actually spent. This is
one of the major failings of the administration of the NDIS that may well bankrupt Australia and be responsible for the death of vulnerable Australians. My question is specifically about the case of David and Sandra Smith. Under their package, they are entitled to some assistance in minor property maintenance. They needed some minor trimming of half a tree and a few branches of another on the property. That was not even completed. They found that $3,000 had been taken out of their package and given to the contractor without discussion between the Smiths and the service administrator of the package. Having raised the issue as a complaint, the Smiths have been ignored. Because of the depleted funds, the Smiths had to cancel some medical appointments they could no longer afford. This issue is gravely affecting their health at an age when they can ill afford such events. The Aged Care Quality and Safety Commission closed off their complaint and refused to even discuss it with the Smiths. They refused to even discuss it, and no explanation was given. To me, this seems like elder abuse by a government agency that is supposed to help older Australians, not abuse them. What is the cover-up, and why was $3,000 paid for next to no work?

Mr Comley: I think the commissioner will provide a response, noting, of course, that it’s difficult for us to talk about individuals in this forum. I will ask Ms Hefren-Webb to comment.

Ms Hefren-Webb: Obviously, I can’t comment on any individual case, and I don’t have any knowledge of the case you’re talking about. We receive around 10,000 complaints a year. Each of them is triaged and assessed, and we do provide a comprehensive response to people. I am not aware that we would ever refuse to provide a response, so I would be very happy to follow up the case you’re talking about.

Senator ROBERTS: So we can put you in touch with them?

Ms Hefren-Webb: That would be great. I’d be very happy to get in touch.

Senator ROBERTS: It does raise issues of accountability, the level of care and the attitude in the department.

Ms Hefren-Webb: It sounds like it’s an issue of pricing that they’re concerned about.

Senator ROBERTS: It might actually be fraud as well.

Ms Hefren-Webb: Potentially. I think the third-most-common complaint we receive around home care is about pricing of services. We do investigate those complaints and we do follow up to see what has driven the
particular pricing. You weren’t here earlier when I said we will compare providers and, if another provider is offering the same service for a lot less, we will ask the provider to explain how they arrived at that price.

Senator ROBERTS: Do you normally get quotes?

Ms Hefren-Webb: We don’t get quotes; we ask the provider how they have come up with their quote.

Senator ROBERTS: So you do not insist on a second quote, but you ask them the source of their quote?

Ms Hefren-Webb: It’s the provider who is managing the package. If there’s a price that the consumer feels is excessive, we will investigate how that’s come about. That’s our role. If we suspect that there is a fraudulent
aspect, we will obviously refer that through to the department, because they’re responsible for fraud and assurance and we’re responsible for compliance with the standards.

Senator ROBERTS: Okay. We will send the contact details.

Ms Hefren-Webb: That would be great.

Senator ROBERTS: Could you check on notice if you have dealt with this or if Aged Care have dealt with this? We would like to know what happened.

Ms Hefren-Webb: Will do.

Senator ROBERTS: This disgrace has badly affected the health of two innocent senior citizens who deserve an answer and money put back into their package. Is that what happens when something is found to be incorrect, wrong or unfair?

Ms Hefren-Webb: I think the department has responsibility for dealing with fraud and how that is dealt with in terms of the individual’s package.

Senator ROBERTS: If there’s something wrong specifically, is the money given back to the aged person?

Ms Snow: I think there would be a range of options. If it’s okay, it might be best to work with the commission really closely to have a look at the case, have a look at what’s been undertaken to date and come back to you.

Senator ROBERTS: Okay. Thank you. I see the caveat, but, if appropriate, can money be put back into their account?

Ms Snow: Yes.

Senator ROBERTS: Thank you. Then there is the case of Mr Gary Bayliss, who had $14,449 taken from his My Aged Care account to replace some worn-out timber rails from a fence. Again the commission failed to take action to remedy the fraud. Now the minister has announced that the concept of co-payments is to be instituted into the aged-care packages. That will mean the cancellation of many services needed by package holders, because they will become unaffordable. Minister, the proposal is that many services will need to be paid for at a rate of least $100 per hour, often at more than twice the market labour rate. An age pensioner cannot afford this. From the absurd to the impossible, this is not care, as I said earlier. It’s abuse. Minister, what can you do to fix this?

Senator McCarthy: Thank you for your questions and the concerns that you’re raising on behalf of your constituents. Clearly, there are many stories there that you’re hearing that really hit at the heart of how people are
feeling in terms of their own care. I will take your questions on notice if that’s okay and get back to you with regard to that particular question.

Senator ROBERTS: Please also take on notice the bigger picture of what can be done.

Senator McCarthy: Sure.

Senator ROBERTS: Commissioner, could you take on the case of Mr Gary Bayliss?

Ms Hefren-Webb: Yes, absolutely.

Senator ROBERTS: Thank you. We’ll be in touch.

During the December 2025 Senate Estimates session with the Fair Work Ombudsman (FWO), I asked about progress on addressing the issue of stolen miners’ wages.

Mr Steve Ronson, representing the FWO, advised that 33 complaints are currently being looked at, and that preliminary findings are close to completion. These findings will enable the parties involved to review their positions and make further submissions if they choose. He also noted that three companies have now self-reported instances of non-compliance, and a total of 25 employers are involved. Several staff members within the FWO are actively working on this matter.

I will not relent until this injustice is fully addressed. Those responsible must be held accountable.

— Senate Estimates | December 2025

Transcript

ACTING CHAIR: I’ll go over to Senator Roberts. Hello, long time, no see.

Senator ROBERTS: Not since yesterday.

ACTING CHAIR: Would you like to have a crack, mate? We are rolling through, and I’d like to give you the opportunity to put your questions to the Fair Work Ombudsman before we move to Senator Kovacic.

Senator ROBERTS: I’m not having a crack. I’m just going to ask some very simple questions.

ACTING CHAIR: That’s code. I know what he’s like.

Senator ROBERTS: Thank you, Chair. No, my questions are really simple. On the matter of complaints from casual coal miners in Central Queensland and the Hunter Valley, where are you up to?

Ms Booth: Thanks for the question, Senator Roberts.

Senator ROBERTS: It’s only really simple.

Ms Booth: We have 33 matters under investigation. Beyond that, I’m going to ask either Mr Campbell or Ms Volzke to add any colour to that response.

Mr Campbell: I’m happy to bring Steve Ronson up as well, Senator.

Ms Booth: Probably makes sense.

Mr Campbell: If you want to start with your specific question, then we can manage it accordingly.

Senator ROBERTS: Just an update.

Mr Campbell: Just an update.

Ms Booth: Where are we up to, Mr Ronson, is the question—the outcome at 33.

Mr Ronson: We’re well advanced with those investigations—there’s the number that Ms Booth just provided—and we’re getting very close to issuing preliminary findings in several cases. The objective of issuing
the preliminary findings is to make sure that both or all parties to a dispute have the opportunity to review what we’ve found in our investigations and give them some time to provide either additional or new evidence or
confirm our findings. We anticipate that, within the next few weeks, the preliminary findings for several cases will be issued. That will then continue in the New Year. We’ve done most of our work in those investigations and we’re now getting up to the point of sharing those findings.

Senator ROBERTS: Roughly, out of the 33, what percentage will have preliminary findings coming out in the next few weeks?

Mr Ronson: Before Christmas, out of the 33 investigations, if we take—sorry, 31 is probably the more precise number—but if we—

Senator ROBERTS: Excuse me, what you mean by ’31 is more precise’?

Ms Booth: That’s just updated from the 33 last—

Mr Ronson: Sorry, it was 33 cases last time we met. There’s been two finalised since then. It’s 31 cases now. Sorry, apologies. Of that number, three are self-reports. The two cases—

Senator ROBERTS: What does that mean, that they made their own complaints?

Mr Ronson: Correct.

Senator ROBERTS: They submitted their own complaints.

Mr Ronson: Three companies have self-reported non-compliance with various elements of the Fair Work Act.

Senator ROBERTS: Employers?

Mr Ronson: Yes. The two cases that I am aware of, the findings that will likely be issued in the next few weeks will cover about four workers. What I can say is that we’re close to issuing findings with two cases that
cover four workers.

Senator ROBERTS: Is that the final decision?

Mr Ronson: Well, what will happen—

Senator ROBERTS: Is it going to vary for each of their complaints?

Mr Ronson: Yes. What we’ll do is issue the findings. The employer, or the employing entities, and the workers will receive the findings, and they will be given an opportunity to reflect on them, look at them and
ensure that they are accurate or, if they want to, contest any part of our findings. If so, they’ll be given reasonable time. Possibly, because it’s Christmas, they’ll be given four weeks or thereabouts. By the end of January, if there’s no additional or new evidence or isn’t any contest, then we’ll proceed to finalising those findings. What we’re hoping is that by January and February we’ll be issuing, progressively and sequentially, more findings, because we’ve done most of the investigation work for those 28 cases.

Senator ROBERTS: When do you think all the 31 remaining will be finished?

Mr Ronson: If I exclude the self-reports and we look at the 28 cases, my view would be that the preliminary findings would be issued through not just December but January, February and possibly early March—so
progressively.

Senator ROBERTS: So the final reports will come about four weeks after.

Mr Ronson: The findings of each particular investigation are about four weeks after the preliminary findings. Unless—say, for example—I issue you a letter and you go, ‘Hang on, you’ve omitted this evidence,’ or, ‘You’re missing this.’ That, of course, might continue the investigation.

Senator ROBERTS: What’s the breakdown, roughly, between Queensland and the Hunter Valley?

Mr Ronson: I’d need to take that on notice.

Senator ROBERTS: Could you, please. And the number of employers involved?

Mr Ronson: From memory, it would be 25.

Senator ROBERTS: Twenty-five employers?

Mr Ronson: Yes.

Senator ROBERTS: I’ll leave it at that. Well, perhaps I will ask a question. Are they labour hire firms or mine owners?

Mr Ronson: I’m happy to take it on notice to provide the particulars of that division, but it’s a mix.

Senator ROBERTS: Okay. And how many staff do you have devoted to this?

Mr Ronson: In terms of dedicated staff, there would be at least three. That’s them putting a considerable amount of their time into just this particular sector, but I’m happy to correct that.

Senator ROBERTS: If it’s not correct, you can provide it on notice.

Mr Ronson: Sorry. I’m happy to confirm it, but it would be about three.

Senator ROBERTS: Okay. Thank you.

Doctors have raised with me their concerns about a lack of accountability and a lack of basic understanding that is evident in reports prepared by the Professional Services Review Scheme (PSRS).

During the December 2025 Senate Estimates session, I asked Professor De Dio of the PSRS about the process for drafting Committee Reports. He explained that the reports are written by Committee members with significant assistance from staff lawyers. The lawyers contribute by reviewing the reports and helping with drafts, ensuring the content reflects the concerns of the Committee members.

Professor De Dio noted that the reports are the result of collaborative work, with lawyers playing an important role in production. A draft report is prepared based on the questions asked and the input of members, after which the Committee reviews the draft. He confirmed that this process is standard practice.

My question regarding who signs off on the reports was taken on notice.

– Senate Estimates | December 2025

Transcript

Senator ROBERTS: This is to the Professional Services Review. Who actually writes the draft and final reports on doctors—PSR lawyers or committee members?

Prof. Di Dio: They are the reports of the committee members, and they are assisted in the drafting of those reports by the PSR’s staff.

Senator ROBERTS: Are they lawyers or staff?

Prof. Di Dio: Usually they are lawyers, yes.

Senator ROBERTS: To what extent is legal assistance involved in the authorship of such reports?

Prof. Di Dio: Sorry?

Senator ROBERTS: To what extent is legal assistance involved in authorship of such reports?

Prof. Di Dio: The committee are assisted by the legal practitioners who form part of the support team at the PSR to a significant extent, but, ultimately, the report is their own. They review the report and ensure that the
report contains their views, their opinions and their assessment as to what the outcome should be.

Senator ROBERTS: How much of a final report is written by lawyers and how much by doctors? I know it would vary.

Prof. Di Dio: It varies very much. I can only reiterate that the report is the report of the committee.

Senator ROBERTS: Which parts are written by lawyers?

Prof. Di Dio: I can’t make it clearer. The report is the committee’s report. Legal officers assist with the drafting but the report reflects, at a very granular level, what the concerns of the committee are in both a generic
sense and in the sense of individual services being reviewed.

Senator ROBERTS: The committee members presumably need to collaborate and co-operate if they’re to produce a final report together. What form does this take? Is it emails, phone calls, zoom meetings, face-to-face
meetings?

Prof. Di Dio: It’s something that occurs in a variety of ways. They also have shared access to technology such as SharePoint and other—

Senator ROBERTS: So they might pass the written report around amongst themselves, modifying it, reading it.

Prof. Di Dio: There are a variety of different ways in which they do it. It is their report.

Senator ROBERTS: What’s the justification for lawyers writing drafts and final reports when the act states that they must be prepared by the committee?

Prof. Di Dio: The committee is provided with support services by the agency in order to do their job. The report is their report.

Senator ROBERTS: Do lawyers ever draft a report or write the final report?

Prof. Di Dio: Lawyers have a role to play in the production of that report. The report is created after a committee has sat for however long it sits for. At that committee hearing, questions are asked by the members of
the committee, and the members of the committee present and clarify their findings with the practitioner under review. A process then occurs whereby a draft report is initiated, but that draft report is based upon an extensive review and analysis of what occurs at the committee and what the practitioners who are members of the committee do and say. So there is a role to be played by the PSR team in the preparation of the draft of that report, but the draft of that report is based upon a variety of pieces of data which are initiated by the members of that committee, whether it is what they said contemporaneously, what they asked, the contents of a transcript. It is the committee’s report.

Senator ROBERTS: So a lawyer may write the draft, but it will be after consultation with the committee?

Prof. Di Dio: That is what may occur, yes.

Senator ROBERTS: Are committee members paid for their work in writing the draft and final reports?

Prof. Di Dio: Sometimes. It depends on whether they request to be paid for their work.

Senator ROBERTS: What sort of role does a committee member have? What are they paid for and what are they not paid for?

Ms Weichert: Committee members are entitled to be paid under the Remuneration Tribunal determination for their input into the draft and final reports. It just depends on whether they submit their timesheet to us to process that pay. The Remuneration Tribunal determination is what sets out what they are entitled to be paid for.

Senator ROBERTS: Assuming that lawyers are not trained in clinical medicine, how can they know if what they are writing is a correct summary of the medical evidence canvassed in meetings? How do you make sure that it’s accurate medically?

Ms Weichert: The committee members do that.

Prof. Di Dio: That’s the whole purpose of the committee members; they conduct their committee meeting, and then they review a draft report at various stages, and they continue to review it.

Senator ROBERTS: How long has this practice been in existence?

Prof. Di Dio: What practice?

Senator ROBERTS: Drafting with lawyers.

Prof. Di Dio: I’m not sure. I suspect it’s been many years.

Senator ROBERTS: Thank you.

Mr Comley: Can I just comment. The practice Associate Professor Di Dio is talking about is absolutely common practice throughout probably all parts of public administration, where multidisciplinary teams with
different aspects will have a hand in the preparation of documents, but there is an authorised person or persons actually accountable for the output. In the same way, there are many products that are prepared for me, but,
fundamentally, if I sign them off, I take accountability for those judgements. Or any other area that occurs—when I think about other regulators, that’s very, very common practice. So what has been described is very common. Finally, that person or that body signing off takes accountability for it, but there are many people who actually prepare the raw materials that go into it.

Senator ROBERTS: Thank you, Mr Comley. What we’re concerned about is a number of doctors who have said there doesn’t seem to be any accountability, and quite often the reports are errant medically, and they haven’t been given a fair go. I’m just trying to find out who would sign off on the reports.

Mr Comley: I think it’s been made clear the people signing off on the report are the Professional Services Review board. They take accountability for it. They take responsibility for the report, but they are assisted by
other people in preparing the raw material before they say, finally, ‘Yes, we are comfortable with that output.’

Senator ROBERTS: Just as you sign some reports—I understand you need to have it legally vetted by a lawyer—who signs off on the report for the committee?

Prof. Di Dio: The committee.

Senator ROBERTS: The whole committee? Each of the committee members?

Prof. Di Dio: I believe so. I can take that on notice, but I believe it’s either the chair or whole committee.

Senator ROBERTS: Mr Comley, the reason for my question is we have had a lot of complaints about the PSR reports, and they appear to reflect, in some doctors’ eyes, a lack of understanding of what’s going on. We’re
concerned about accountability. Thank you for your comments.

I spoke with Dr. Marcelle Noja, who expressed sympathy for those whose health has been compromised by mesh complications.

When asked about the Australian Pelvic Floor Procedure Registry’s failures in following up with patients, she stated that this question would be taken on notice.

I also inquired about the steps the government is taking to assist with the cost of remedial surgeries; this question was likewise taken on notice.

Regarding the differences in approach taken by the UK and New Zealand—where mesh has been banned or severely restricted—I was informed that, because the mesh is used for other treatments, Australia has decided against a total ban on the product.

Due to time constraints, I will submit the remaining unasked questions on notice.

— Senate Estimates | December 2025

Transcript

Senator ROBERTS: Let’s move on to pelvic mesh. Following a Senate inquiry, a formal government apology, overwhelming evidence of harm and international bans in multiple countries, transvaginal mesh
continues to be implanted in Australian women daily. Can you explain why these devices have not yet been banned and what specific evidence would be required for the health department to recommend an immediate hold to their use?

Dr Noja: Thank you for this question and thank you advocating for many of the patients who have had urogynaecological mesh and had negative outcomes as a result of it. The TGA was similarly concerned with the
impacts of urogynaecological mesh. That is why we have taken a number of actions in relation to this. When we look at postmarket activities in relation to mesh, and in fact all products, we undertake a risk analysis, we look at the evidence, and we go to the companies and ask them for information in relation to those products. When it came to these products, we did look at the products and we found that, for many, the evidence was not there to support their ongoing inclusion. Many of those products were actually removed from the Australian Register for Therapeutic Goods. However, for some of the products, we did find that, for some health conditions, there was still benefit for patients. So, for those products, we have continued to include them in the register. However, in support of patients, we have done other activities. We have undertaken a number of reforms. Some of those include increasing information for patients. That means more information about the product, more information about what may occur and working closely with the health professionals to make sure that information does get to consumers. We’ve also recently implemented mandatory reporting regulations for mesh. What we found was that the TGA did not have significant signals to be able to act on doing something. Under this new regulation, it will be mandatory for healthcare facilities to report all adverse events to us. We will then be able to pick up signals sooner and act faster. We continue to monitor this, and this includes undergoing ongoing signal-detection activities. These are critical devices for some Australians, so we really have to be balanced in what we remove from the register versus what we allow to continue, as well as how patients can access it.

Prof. Lawler: I’ll add briefly, as Dr Noja has said, that the role of the regulator is to understand the balance between the risk to patients and the benefits to patients. As we’ve heard, there are certain instances with certain products and certain conditions where there continues to be strong benefit. One of the roles that we take as a regulator is to regularly update product information so that the information that’s necessary for patients to make informed decisions is available to them for conversation with their registered health practitioner.

Senator ROBERTS: Dr Noja, perhaps you can correct me on this, but this is my understanding—I take note of what you said—on the back of the 2018 inquiry, a pelvic mesh registry, the Australian Pelvic Floor Registry, was established. Unfortunately, this registry fails to track long-term health outcomes of mesh affected women, because it only tracks certain women from certain hospitals and only for a period of 24 months. That may have changed. You can correct me if I’m wrong. Will the government amend the failings of the Australian Pelvic Floor Procedure Registry and instead establish a comprehensive, long-term health monitoring program?

Dr Noja: Responsibility for the pelvic floor mesh registry doesn’t sit with the TGA; it sits with my colleagues in another part of the department. I’m not sure if our colleagues from HERD are here. I don’t believe they are. We can take that on notice and talk to our colleagues to provide you with an answer.

Senator ROBERTS: Thank you. The mesh clinics established after the 2018 inquiry are fundamentally failing women by providing only partial medical intervention. Apparently these clinics will remove mesh devices
but categorically refuse to repair the resulting extensive damage, leaving women in a state of severe medical compromise. Can you explain why these clinics are permitted to create additional harm?

Prof. Lawler: We’re not familiar with the practices of those clinics. The regulation of clinics and health practitioners is not a responsibility of the TGA, and, as I mentioned previously, these are largely conversations
between patients and their treating health practitioners. We are not responsible for the management of the operation of those clinics.

Senator ROBERTS: Can you give any advice to women who are still in a lot of pain—not medical advice, but where to go?

Dr Noja: The TGA has established a range of information on our website. We have what’s called the mesh hub, and I’m happy to provide that link to anyone in the committee, if that’s helpful. The mesh hub includes a
range of information for people who have suffered from mesh injury. It includes information about accessing various aspects of our Medicare system as well as treatment options and information about other services that are available to them.

Senator ROBERTS: The mesh hub?

Dr Noja: That’s correct.

CHAIR: Senator Roberts, I’m just flagging that I will need to shift the call shortly.

Senator ROBERTS: I’ll keep sprinting.

CHAIR: You’re in the sprint, yes.

Senator ROBERTS: Every day Australian women are facing an impossible choice due to pelvic mesh complications—and I’m sure you’re aware of that—draining their retirement savings and suffering ongoing
medical trauma. Many women are forced to access their superannuation on compassionate grounds to fund critical mesh removal or repair surgeries, while others completely forgo necessary care due to prohibitive costs. What steps will the government take to establish a comprehensive support system for women that covers the full cost of surgeries and ongoing care that they need from being harmed by a government-approved medical device? Perhaps the minister might want to comment, as well as you, Dr Noja.

Dr Noja: I will allow the minister to comment, but I will just note that our website does include information for patients with respect to what services they can seek support with. There are a number of MBS and PBS items available to them, which they can seek access to, and there are a number of available resources there for them.

Senator Green: For completeness, I’ll take your question on notice so I can provide you with some information about what supports are available. I don’t disagree with you that these women have gone through an
awful ordeal. I’m confident that we’ll be able to give you some fulsome information about what’s available, but you should continue to raise these issues.

Senator ROBERTS: Last question in this sprint—the UK, Scotland and New Zealand have banned or severely restricted transvaginal mesh use, due to unacceptable harm rates, but Australian women continue to
receive these implants daily. That doesn’t seem to make sense to me. What makes Australian women different from British or New Zealand women and justifies continuing a practice that other countries apparently have
deemed too dangerous?

Dr Noja: I will note that the TGA doesn’t tend to ban devices. Our approach is around inclusion versus exclusion of products so that there remain a number of pathways available to clinicians should they deem it
appropriate for a member of the public to have access to a product. The reason we don’t ban products is that it is important that patients get the best appropriate care for their individual circumstance. I really respect your
comments around what we are doing to protect women, and, as I mentioned, we have actually undertaken a number of actions specifically related to these products. As part of our post-market review and our action, we did upclassify some products and remove others, but it is important that these products remain available. They are used for other surgical procedures, apart from urogynaecological conditions, so it is important we make sure that access is available. We just have to have rigour around where access occurs to ensure that the products are fit for purpose in how they’re being used. Part of that, really, is the patient information and making sure that patients are appropriately provided with all the information they need to support them in making sure that it is the right decision for them.

Senator ROBERTS: I hear what you say, and I acknowledge it, but why is the mesh banned in other countries and not banned here?

Dr Noja: I don’t believe it is banned in other countries. Australia has taken the step to upclassify these products. Other countries have not gone as far as Australia has, in terms of its regulatory approach. Some
countries are continuing to look at these products and make decisions about what they do, but they will be making those decisions based on the evidence they have in front of them and the signals and risks that they’ve seen in the patients that are presenting in their jurisdiction.

Prof. Lawler: In your question you did say that in other countries these products have been banned or significantly restricted. As Dr Noja has indicated in her answer, we have also undertaken some actions that have
restricted those devices, through the upscheduling and through the removal of some from the register, and also through the imposition of conditions of inclusion. So we have taken regulatory actions as well.

Senator ROBERTS: So you’re going to send me more information and the minister is going to give me an answer on notice, and I’m going to stay on the treadmill.

At Senate Estimates, I raised key questions about workplace gender equality and family policy. I asked the Workplace Gender Equality Agency to state executive salaries — the head earns $313,000.

I highlighted to them that the agency itself has a gender pay gap in favour of women — women earn $111,746 vs men $106,141, and that 17 women hold executive roles compared to just 2 men.

My message: Equality should mean fairness and choice — not ideology or quotas.

— Senate Estimates | October 2025

Transcript

Senator ROBERTS: Thank you for appearing today. My questions are entirely to the Workplace Gender Equality Agency. Can everyone who is executive level or senior executive service at the desk state their salary please.  

Ms Wooldridge: I, as the accountable authority, have a remuneration tribunal determination, with a total remuneration of $313,000.  

Senator ROBERTS: Thank you very much. What is a woman? It’s not a trick question.  

CHAIR: Senator Roberts.  

Senator ROBERTS: This is the agency in charge of workplace gender—  

CHAIR: No, this is a political experience here that none of us want to listen to.  

Senator ROBERTS: I’m going to be getting into figures in a minute, so I need to be sure. What is a woman?  

Ms Wooldridge: I’ll refer to our act, which does define a woman. This is the Workplace Gender Equality Act 2012, and it says: woman means a member of the female sex irrespective of age.  

Senator ROBERTS: Does a man who identifies as a woman count in your statistics for women—in looking at your staffing statistics, for example?  

Ms Wooldridge: I’ve defined a woman as per the act, and we apply the act in terms of the operation of our agency and our reporting.  

Senator ROBERTS: Does that mean a man who identifies as a woman is not a woman in your staff classifications?  

Ms Wooldridge: Senator, once again, I’ll refer you to the definition under the act.  

Senator ROBERTS: In your application of that definition, is a man who claims to be a woman, identifies as a woman, listed as male or female?  

Ms Wooldridge: Perhaps it would assist to clarify that, in terms of reporting to the agency, the employers who are relevant employers—with 100 or more employees—are required to report to us every year. They are asked, for their employees, who are men and who are women. We also collect, voluntarily, data for people who identify as non-binary. So employers have those three categories on which they can report their employee data to us.  

Senator ROBERTS: Men, women and non-binary? Okay, thank you. In response to question on notice 97, you’ve reported the salary for women and men employed in your department. By the way, that figure shows that the average salary for women in your department is $111,746 and the average salary for men is $106,141. That’s a five per cent pay difference, so you have a pay gap against men.  

Ms Wooldridge: We have a gender pay gap that’s negative. That’s right.  

Senator WHITEAKER: Chair, on a point of order, I’m just not sure how the question is relevant to the work of the department.  

Senator ROBERTS: You’re not sure?  

Senator WHITEAKER: No.  

Senator ROBERTS: This is the Workplace Gender Equality Agency.  

CHAIR: Yes, Senator Roberts.  

Senator ROBERTS: I’m checking to make sure they’re working—  

CHAIR: I do have a level of sympathy with Senator Whiteaker’s frustration here at what appears to be heading down an overtly political and somewhat offensive pathway. Ms Wooldridge, I would encourage you to only answer the questions that you feel to be relevant to your agency and relevant to Senate estimates.  

Senator ROBERTS: Chair, what is offensive about the question I just asked? This woman is in charge of informing—  

CHAIR: Senator Roberts, we all know where you’re going.  

Senator ROBERTS: Oh, do you? Okay, up to you.  

Ms Wooldridge: So, yes, we have a negative gender pay gap. Eight per cent of employers that report to us have a negative gender pay gap, which reflects an average total remuneration slightly higher or higher for women than men. But we do know that the vast majority of employers in Australia do have a gender pay gap in favour of men, which is a positive gender pay gap. That’s a normal calculation that we make for employers in Australia.  

Senator ROBERTS: You have 38 full-time workers and three part-time; 29 female, 11 male and one nonbinary. With your gender pay gap favouring women, doesn’t it show how ridiculous the entire concept of trying to equalise aggregate wage is?  

Ms Wooldridge: We’ve discussed before the definition of the gender pay gap. We believe that it’s a very valid measure as a proxy for gender equality. It’s used very effectively; it’s used internationally—around the world. Each individual employer has a different result, and we encourage them to reflect on their results and look at how the gender pay gap can be narrowed to ensure we have a greater equality in our workplaces.  

Senator ROBERTS: Reading your staffing breakdown, from the question on notice, you had 17 women employed at executive level or higher. I understand executive level starts at $120,000 a year. There are 17 women employed at that level and above and only two men. Is that your definition of gender equality.  

CHAIR: That could only be said by a man, right?  

Senator ROBERTS: I happen to have been educated by my mother.  

Senator Wong: Unless Ms Wooldridge wants to, I might just respond briefly, Senator. I understand you have a view about this agency. You’re entitled to that. We disagree with it.  

Senator ROBERTS: What is my view, Senator Wong?  

Senator Wong: Alright, maybe you don’t have a view. I was inferring it from your questions. But could I say this: I think the proposition that, because in this one agency there are more women on high salaries than men, the gender pay gap is not relevant is a very odd one. We have ABS statistics which still show a gender pay gap of 11½ per cent. WGEA statistics, which use different methodology—I think that was the evidence before—show it in excess of 20 per cent. It’s not the only way in which we look at equality, but it does tell us something. It tells us that our daughters are likely to earn less than our sons. That’s not merit based, and there are reasons for that. Some of those reasons may be valid and some of them may not. So it is one of the ways in which we try to improve the economic equality of our society, and I would argue it’s of benefit to everybody. Yes, it benefits women, but I think it is of benefit to all of us if we work to remove those barriers to the full participation of women and men in the workplace.  

Senator ROBERTS: I would agree with you. I do agree with you, Senator Wong. In fact, I’ll pay you a compliment; I hope it’s well received. You are one of the outstanding performers in the Senate. I don’t agree with some of your policies, statements and values, but you’re one of the outstanding performers. You’re not equal to everyone else in the Senate; you’re far superior to many. That’s no doubt.  

Senator Wong: I don’t know quite what to do with this, Senator Roberts. This is probably not good for either of us!  

Senator ROBERTS: No, it’s certainly good for me, because we compliment people when they deserve it, and you deserve that recognition. My mother told me the sad mistake is for women to claim they’re equal, because in many ways women are far, superior to men—far, far superior. That’s on the record.  

Senator Wong: There you go.  

CHAIR: Senator Roberts, we need to wrap up.  

Senator ROBERTS: It’s not just because my party leader’s a female.  

CHAIR: I will just advise you that we’re going to break for lunch in two minutes, Senator Roberts. Those two minutes are all yours.  

Senator ROBERTS: Okay. The replacement family rate is on average 2.2 babies per couple. That inevitably leads to women being out of work for pregnancy just so we don’t go extinct in our species. What adjustment do you make to calculations to account for the fact that we do need to have babies and it’s a good thing, or Australia goes extinct?  

Ms Wooldridge: The gender pay gap is calculated by looking at average salaries between men and women in an employer, in an industry or in the nation as a whole. One of the things we do know, though, is that a very significant portion of the gender pay gap is attributable to the time women take out of the workforce to care for family and responsibilities.  

Senator ROBERTS: Thank you.  

Ms Wooldridge: So the gender pay gap is reflective of that, but there are many things that employers can do to minimise the impact of that time out of the workplace in order to encourage women who need to, or want to, to be able to engage with work as well as manage caring responsibilities.  

Senator ROBERTS: Acknowledging what you just said, Ms Woolridge, isn’t it true that, for the gender pay gap to be completely erased, we have to either stop women having babies or have them work the day before and the day they give birth?  

Ms Wooldridge: I disagree with you, Senator. In fact, there are many employers who do have zero gender pay gap and who are able to create that equal and fair experience at work. But we do acknowledge that, yes, there are some aspects of the gender pay gap that are attributable to the time out of the workforce, and I think we’re aspiring to minimise the gender pay gap so that those inequalities at work are removed and people do have an equal experience.  

Senator ROBERTS: Last question, Chair.  

CHAIR: Senator Roberts, we are going to wrap up now, because we’re already running late. I can come back to you after the break if required.  

Senator Wong: We’d be happy with one more question.  

CHAIR: Just one?  

Senator ROBERTS: Yes. It’s for the minister, and I thank you, Minister. Mothering is the nation’s most important job. The critical years for formation of both character and intellect are from birth to six, and the mother shapes that enormously. Granted, for some couples, the mother works and the father stays home or whatever. That’s a choice. Women and men deserve choice. The tax system eliminates choice, and mass immigration drives down wages. What are your view on income splitting as a policy to adopt?  

Senator Wong: That is probably not for this group, but the government is supportive of a progressive taxation system. We are also supportive of putting in place policies that contribute to stronger families and parenting. You have seen support for parents. You’ve seen what we’ve done in the areas of health, child care and education.  

CHAIR: Senator Roberts, from a personal perspective, as a single mother, I had an extraordinarily flexible employer. I must say it does make a fundamental difference to your life to have an employer who understands the value of giving you space to bring up your children and equally deliver on your responsibilities at work.  

Senator ROBERTS: Of course, and an enlightened employer hires people of all kinds of backgrounds for that very reason. 

When I look at the NDIS and NDIA, I see a system full of contradictions—balancing fraud prevention with accessibility has been a challenge since its inception. In this Estimates session, I focused on fraud and the work of the Fraud Fusion Taskforce. I raised concerns about the gap between over 7,000 tip-offs in the June 2024 quarter and only 16 prosecutions. While I understand investigations are complex, that disparity is striking. Officials explained that not every tip-off is valid; many are misunderstandings or even malicious.

Since November 2022, the taskforce has achieved over 300 compliance outcomes, including bans and revocations, and significantly increased enforcement activity. They highlight that prosecutions are a slow and unreliable metric, pointing instead to indicators such as 35 warrants executed in the first four months of this year—a twelvefold increase from previous years. Custodial sentences and asset seizures have occurred in cases involving millions of dollars and dozens of properties, including seizure orders on 33 houses and multiple vehicles. These results demonstrate that serious fraud is being tackled, even if the full impact takes time to show.

Mr Dardo stressed that success should not be measured by debts, prosecutions, or raids, but by prevention. The Crack Down on Fraud program focuses on identity verification, stronger evidence requirements, and advanced data analytics to detect risks early. These measures aim to make compliance easy and fraud difficult, safeguarding participants and ensuring sustainability. While prosecution remains a tool, the ultimate goal is to reduce fraud so effectively that legal action becomes rare. A recent survey revealed that 899 out of roughly 1,000 plan managers showed indicators of potential fraud, underscoring the need for these preventive systems.

I commend this approach because it makes sense: prevention first, enforcement when necessary. Still, some people will always try to bypass safeguards, and the scale of fraud remains daunting. Australians deserve confidence that the NDIS is fair, secure, and sustainable. We must continue improving systems while maintaining transparency and accountability. Striking the right balance—protecting participants while cracking down on fraud—is critical, and I will keep pressing for progress on both fronts.

The agency appears to be delivering every milestone of its Crack Down on Fraud program on time and under budget, with independent audits and ANAO oversight ensuring accountability. That level of scrutiny and systems uplift is encouraging, but the journey is far from over.

— Senate Estimates | December 2025

Transcript

Senator ROBERTS: Thank you for being here today. I have some questions. It’s very much a contradictory set of questions. I have questions about fraud and questions about how to make more people eligible. The whole NDIS, NDIA, seems to be full of contradictions, from the moment it started back in 2010 or whenever it was.  Could I ask questions about the Fraud Fusion Taskforce first, please. I have some NDIS data—I’m not sure exactly where it came from, but it’s from within the NDIS—that says that for the June 2024 quarter there were over 7,000 tip-offs, but only 16 prosecutions for fraud. Why has the taskforce achieved only 16 prosecutions in a quarter despite 7,000 tip-offs? Can you explain the gap? And I’m not pretending that it’s easy. 

Mr Dardo: The tip-offs that we receive may be treated through a range of mechanisms. It might be that we look at them and we’re able to engage with a provider or a participant and deal with them through education. The tip-off may require us to implement some sort of prepayment review where we would nudge a person to give us some evidence before we make a payment, and maybe we would do a post-payment review, a historic review. It may be that we do a more serious administrative compliance intervention and it may be that we implement manual payment reviews where we stop payments until we receive evidence for each claim. In the most extreme cases, we may revert to a criminal investigation and/or prosecution. It’s really important to note that there’s a spectrum of treatments, depending on the severity of the tip-off and the efficacy of the tip-off. In some cases, we look at the tip-off and it’s actually a misunderstanding, and there’s no substance underneath it that requires an intervention. 

Senator ROBERTS: So, the tip-off itself is wrong? 

Mr Dardo: It might be wrong, or it might be a misunderstanding. In some cases, it’s malicious—somebody having a go at someone else. So, it’s really important that, while we do measure tip-offs and while we have put in enormous programming to improve the way we capture, understand and process tip-offs, the volume of tip-offs alone does not indicate the requirement for a prosecution. While I am talking about tip-offs, once upon a time tip-offs used to be captured, effectively, on a spreadsheet. We have put in a range of system improvements to make the tip-offs more able to be captured in a codified way. So, whether it’s through the call centre or through our online systems, they’re able to be captured in a way where we can code and then analyse the content of the tip-offs. The beauty of that is that, as the volumes have increased—and they are increasing; they continue to increase—we’re more able to run  analytics over the top of them and understand whether the tip-off relates to previous tip-offs or previous treatments or previous risks, then cluster them or group them with associated intelligence or associated treatments. The systems continue to improve by the week, but I don’t want you to assume that every tip-off is going to lead to a prosecution. That would never be the case.  

Ms Myers: As members of the Fraud Fusion Taskforce who work very closely with the NDIA, since November 2022, we have executed over 306 compliance outcomes, including 179 banning orders, 38 revocations of registration and 89 other regulatory outcomes. So, in addition to the prosecutions undertaken, there have been a number of regulatory actions taken. 

Senator ROBERTS: So, restrictions have been imposed and bans et cetera. 

Ms Glanville: I think the really important piece of this is that it’s a very collaborative arrangement between the NDIA and the commission as well as other enforcement agencies. The development and growth of that, I think, has been particularly positive for being able to identify—better analyse, as Mr Dardo was saying—and understand what are the best actions that can be taken to address whatever is the nefarious or other action that has occurred. I think that’s a really important part of this process as well. 

Senator ROBERTS: So, it is a big issue to you, the NDIS and NDIA. 

Ms Glanville: To the commission and the agency, yes. 

Senator ROBERTS: It’s also a matter of restrictions, but I’ll go to total prosecutions and convictions for NDIS fraud. How many since the taskforce was established? 

Mr Dardo: I think, again, it’s really important that we step back. It’s a metric that has a significant lag effect. 

Senator ROBERTS: Due to the court system plus the investigation? 

Mr Dardo: Yes. You may start something and there may be interventions that are lower-level interventions or they may rapidly escalate. Before search warrants are executed—in some cases it’s very, very fast. It could be weeks or a month. In some cases it takes longer. But, even after search warrants are executed, sometimes there’s a charge on the day, sometimes there’s a court attendance notice, and sometimes it takes another six to 12 months to get to a charge and then to get in front of the courts. In some cases we’re seeing cases not getting in front of the courts for several years.  So can I just flag that the number of prosecutions is not a number that’s a great indicator of the level of activity that is occurring, and it’s certainly not a number that reflects the enormous collaborative effort that’s occurring across the agencies. Our colleagues at the commission have been phenomenal in partnering with us, as have been a number of other agencies—Services Australia and the tax office and so on. So sometimes the interventions are actually better administered by other agencies or in partnership with other agencies. If you want something that’s a more indicative number of activity at that sharp end, like the activity that you’re trying to get to, at the very tip of the iceberg—just in the first four calendar months of this year, we did 35 warrants. That’s more than were done in four whole years before the taskforce was established, and that was just in the first four months. So, if you’re looking for an indicator of sharp activity, we’re talking a 12-fold increase in activity in a taskforce. And that doesn’t even scratch the surface of the things that happen underneath investigations—the interventions that are going on.  

Senator ROBERTS: It’s pretty daunting. I don’t know if it was you—I think it may have been you—who, a year or so ago, told us that you were overwhelmed and that the court system would not handle it.  

Mr Dardo: It’s really important to note—and I’ve said this a number of times on the record in this house—that debts, prosecutions and raids are the wrong metrics for a successful system. What we really are trying to build through all our big investments is how you prevent those bad things from happening. If you look at the big system investments we’re making, they’re trying to figure out how you make it easy for people to get it right and really hard for them to get it wrong. That means that all the people trying to do the right thing, which is the majority, are having a better experience. It’s more streamlined, it’s easier for them to get paid the right amount, and they’re less likely to get themselves into a misunderstanding and less likely to be abused by a non-compliant provider. That upfront prevention is, overwhelmingly, our mission. Everything we’re building in the Crack Down on Fraud program is about building prevention upfront so that you can safeguard participants and get sustainability—whether it be improving the identity systems for the people that log in, which we’ve delivered; whether it be improving the identity systems for the providers, which we’ve now delivered; whether it be improving the evidence requirements for claiming so we’re more confident people are getting it right, which we have partially delivered and continue to improve; whether it be building a data analytics system that allows all that data to be pooled together so we can identify risks and stop at prepayment where we can; or whether it be working with our partners to have those risk detections so that we can identify problematic providers and exit them from the system at the earliest opportunity. All those things that prevent bad things happening have to be the focus. You’ll never get rid of the need to raise debt or prosecute; that will always be something in the arsenal. We will need to be good at it, but it should be the last resort. You would hope whoever replaces me in two or three or four years time is sitting here, saying, ‘Actually, we only had to do five prosecutions because the systems work so well that we didn’t have to prosecute.’ 

Senator ROBERTS: What you’re saying makes perfect sense. Nonetheless, some people will deliberately bypass just about everything. 

Mr Dardo: Yes. 

Senator ROBERTS: Deliberately.  Have there been any custodial sentences handed out? 

Mr Dardo: There have been, absolutely. Not only have there been custodial sentences; there have also been successful confiscations of assets. There are people that have gone to jail and are serving custodial time. There are people we’ve grabbed $4 million or $5 million worth of assets from. We have cases in progress right now where we’ve worked with partners, whether it be state or federal, to put seizure orders on, in one case, 33 houses and three cars. Let me emphasise: that was a provider. Custodial is in the toolset, but remember: custodial has got to be an outcome from the courts. We don’t get— 

Senator ROBERTS: Which can take months and months. 

Mr Dardo: It can take years. At the end of the day, the court makes the decision about custodial. We put our best case in the brief, the CDPP puts the best case in front of the courts, and the courts make the decision. 

Senator ROBERTS: I’ll say it again on the record: what you’re saying makes perfect sense. I commend you for that. I don’t know whether you’re doing a good job or not, but it sounds like the right approach to me. 

CHAIR: How much more time do you need, Senator Roberts? 

Senator ROBERTS: Probably five minutes, please, Chair. 

CHAIR: Okay, no problem. 

Senator ROBERTS: My subsequent questions are not really necessary because of the comprehensiveness of your answer. 

CHAIR: Can you put them on notice then? Is that what you mean? That’s a no. 

Senator ROBERTS: Apparently, you stated that a survey showed 90 per cent of a group of plan managers exhibited signs of fraud. 

Mr Dardo: Absolutely. 

Senator ROBERTS: How many of those cases have been referred for criminal prosecution? 

Mr Dardo: That was a discussion that I’m pretty sure we had in a previous Senate estimates. It was a particular subset of plan managers, so it wasn’t every plan manager. It was the plan managers that had between zero and 100 clients. I know that sounds weird, but you can have zero clients because you had clients and you’re not claiming for them right now. There were roughly a thousand plan managers with between zero and 100 clients in that sample, and about 899, to be exact, at the time we did the analysis had indicators that we would think are associated with potentially fraudulent behaviour. Again, there are a range of interventions that we’ve applied there. In some cases we have put prepayment reviews on them, where they can’t be paid unless they provide evidence for their claims. If those prepayment reviews turn up and provide evidence that’s problematic—we look at it and we go, ‘That looks like you’re falsifying your invoices, claiming for things that are not remotely connected to the scheme or claiming for participants that are not getting a service’—then we will work with the commission to remove them from the scheme. That’s an intervention that may or may not go to a prosecution. The other intervention we’ve applied is that we’ve made requests for information for historic claiming and we’ve gone back and looked at their historic claiming. We’ve just done another sample of 47 where the majority of those have problematic claims, so either we’ve referred them to the commission for banning or we have removed their ability to claim from us. We’re working through those.  In some cases we executed search warrants with our partner agencies. In one case, we, the commission, the tax office and some other regulators targeted the plan manager. We got access through a search warrant, a tax debt was raised, and there were banning orders from the commission and other regulators to remove them from multiple schemes. That case may proceed to prosecution, and we’ll work our way through it. In that case, debts were also raised from multiple agencies.  So there’s a spectrum of treatments. We are not going to prosecute every single plan manager that we said had fraud indicators, and there may be some where we look at them and we go, ‘The fraud indicators are there, but they didn’t lead to anything.’ 

Senator ROBERTS: Final question—how will you know you’re being effective, and how will we know you’re being effective? How will we know when fraud is out of the NDIA? 

Mr Dardo: Fraud will never be completely out of the NDIA, just like it’s never out of any scheme. There will always be a level of it that just exists. You have to continue to innovate because it’s an arms race to stay ahead. 

Senator ROBERTS: But, right now, the stories are rife. 

Mr Dardo: They are. It’s about continuing that work for prevention. That has to be the overwhelming focus. 

Senator ROBERTS: How will we know if Mr Dardo has done a good job? It sounds good. I’m not being patronising. I sincerely mean that. It sounds good. What you’re saying makes perfect sense in managing the process. It is what very few managers understand. How will we know that the process has good outcomes? 

Mr Dardo: The first time I came here representing this agency, I sat in this room, and we rattled off the half a-dozen things that needed to be built out as capabilities. We talked about the vulnerabilities in the scheme and about identity, the way claiming was working and the way providers were interacting. We rattled those things off.  When we sat down and imagined the program of work that addressed those things, which government funded, that program of work clearly articulated those layers of capability that needed to be built and delivered. You build 

the foundations, and then you’ve got to keep building. But we laid that out as a program of work called the Crackdown on Fraud program—the systems uplift. That systems uplift was funded by government. In February 2024, it commenced. We delivered every single milestone in that program of work between February 2024 and now, on time and under budget. Let me rephrase that slightly—within the timeframes that we promised we would build it. We started two months later than we said we would, so a couple of things have finished a couple of months later than we said they would. But it was built within the timeframe we said we would build it.  One indicator for you that we’re doing a proper job is we are building those layers of defence on time, and, as they go into production, we can actually see that we’re stopping things from happening that used to happen or that used to be completely invisible. We are now more confident that some of those things we promised would be there are there. The journey is not finished; we’ve got a long way to go. But it’s about how we deliver on those promised uplifts so that the system is less likely to be open to abuse by those who want to abuse it. 

Senator ROBERTS: Would you include in that an audit of the systems, to make sure the systems are working as you say? 

Mr Dardo: I can assure you that we’ve got eyes—not just our eyes but everyone else’s eyes—on it. The ANAO comes and looks at us and makes sure that we’re actually building what we said we were going to build and building it on time. The Department of Finance gateway reviewers come and look at us and say: ‘You promised this. Did you build it? Has it been delivered on time?’ So, there is an enormous amount of independent assurers coming and looking at what we promised for the money that we got and whether we’ve built it to the standard that we said we would. In addition to that, we’ve got independent assurers that work on the program with us who write reports for government about whether we’ve delivered what we said we would on time and on budget. The scrutiny is impeccable. 

Senator ROBERTS: Thank you. Thanks, Chair. 

CHAIR: Thank you, Senator Roberts.